<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339923</url>
  </required_header>
  <id_info>
    <org_study_id>V72_28</org_study_id>
    <nct_id>NCT01339923</nct_id>
  </id_info>
  <brief_title>A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years</brief_title>
  <official_title>A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is aimed at assessing the safety and immunogenicity of rMenB+OMV NZ when
      administered alone without routine infant vaccines to healthy infants in their first year of
      life according to different two and three dose immunization schedules, which are suitable to
      be adopted by various national programs. This study will also investigate antibody
      persistence post primary series and administration of a subsequent booster dose of rMenB+OMV
      NZ at 11 months of age. In addition, this study will assess the safety and immunogenicity of
      two catch-up doses of rMenB+OMV NZ when administered to healthy children 2 to 10 years of
      age.

      This study will also evaluate the safety and immunogenicity of the concomitant administration
      of rMenB+OMV NZ with meningococcal C conjugate vaccine (MenC-CRM) according to a 3, 5 and
      12-month schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of rMenB+OMV Vaccination.</measure>
    <time_frame>1 month after second vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254 and hSBA titers ≥ 5 against strain M10713 following 2-dose primary series of vaccination with rMenB+OMV NZ at 3.5 and 5 months of age or at 6 and 8 months of age. Analysis was done on Full analysis set (FAS)-Primary series.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 4, hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 3-dose Primary Series of rMenB+OMV Vaccination</measure>
    <time_frame>1 month after third vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713, following 3-dose primary series of vaccination with rMenB+OMV NZ at 2.5, 3.5 and 5 months of age. Analysis was done on FAS-primary series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</measure>
    <time_frame>1 month after second vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule). Analysis was done on FAS-primary series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving Four-fold Rise Over Baseline hSBA Titers Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</measure>
    <time_frame>1 month after second vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects achieving 4-fold increase in hSBA titers as compared to baseline against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule).
Analysis was done on FAS- primary series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) Following 2 or 3 Dose Primary Series of Vaccination With rMenB+OMV</measure>
    <time_frame>1 month after primary series vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains following 2 or 3 dose primary series of vaccination rMenB+OMV NZ (1 month after 3rd infant vaccination in B_2h3h5_11 and 1 month after 2nd infant vaccination in B_3h5_11, B_68_11 and B_02).
Analysis was done on FAS-primary series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) After First Infant Vaccination With rMenB+OMV.</measure>
    <time_frame>1, 1.5 or 2 months after first infant vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (after 1 month for group B_2h3h5_11b, 1.5 months for group B_2h3h5_11b and 2 months for group B_68_11b). Analysis was done on FAS-post first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 After First Infant Vaccination With rMenB+OMV</measure>
    <time_frame>Post- first dose (1 month for B_2h3h5_11b, 1.5 month for B_3h5_11b and 2 months for B_68_11b after 1st vaccination)</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (at 3.5, 5, and 8 months of age respectively). Analysis was done on FAS-post first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 Following a Booster Dose of rMenB+OMV Vaccination</measure>
    <time_frame>1 month post-booster dose</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following a booster dose of rMenB+OMV NZ given at 11 months of age (4th dose for B_2h3h5_11 and 3rd dose for B_3h5_11 and B_68_11). Analysis was done on FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Persistence in Terms of Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</measure>
    <time_frame>11 months of age (persistence)</time_frame>
    <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ vaccine. Analysis was done on FAS-persistence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Persistence in Terms of Geometric Mean Titers Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</measure>
    <time_frame>11 months of age (persistence)</time_frame>
    <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of GMTs against N meningitidis serogroup B indicator strains in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ. Analysis was done on FAS-persistence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following 2 or 3-dose Primary Series and Booster Dose of Vaccination With rMenB+OMV NZ</measure>
    <time_frame>1 month after primary vaccination, pre-booster vaccination (persistence) and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, following 2 or 3 dose primary series and booster dose of rMenB+OMV NZ. Analysis was done on FAS-persistence and FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 After a Two Dose Catch-up rMenB+OMV NZ Immunization Series in Children 2-10 Years of Age</measure>
    <time_frame>1 month after second vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, after a two dose catch-up immunization series with rMenB+OMV NZ in children 2-10 years of age. Analysis was done on FAS-primary series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 8 Against Serogroup C Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</measure>
    <time_frame>Baseline, 1 month after second vaccination and 1 month after booster vaccination</time_frame>
    <description>Non-inferiority of MenC-CRM was determined following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months, as measured by the percentages of subjects achieving hSBA titers ≥ 8 against serogroup C. Analysis was done on PPS-primary series and PPS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</measure>
    <time_frame>1 month after second vaccination, 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone - Persistence</measure>
    <time_frame>Pre-booster vaccination (persistence; 12 months of age)</time_frame>
    <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</measure>
    <time_frame>1 month after second vaccination and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and a booster at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs Against N. Meningitidis Serogroup B Strains Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</measure>
    <time_frame>1 month after second vaccination, pre-booster vaccination and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence and FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</measure>
    <time_frame>1 month after second vaccination, pre-booster vaccination and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary and FAS-booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM - Persistence</measure>
    <time_frame>Pre-booster vaccination (persistence; 12 months of age)</time_frame>
    <description>Immunogenicity was assessed in terms of GMTs against Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination With rMenB+OMV NZ</measure>
    <time_frame>Within 30 minutes after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects who reported immediate reactions within 30 minutes following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following a 3 or 4-dose Regimen of rMenB+OMV NZ</measure>
    <time_frame>Day 1 to day 7 after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or as a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination - Groups B_02_2_5 and B_02_6_10</measure>
    <time_frame>Within 30 minutes after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2 - 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic AEs in Groups B_02_2_5 and B_02_6_10</measure>
    <time_frame>Day 1 to day 7 after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2- 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any rMenB+OMV NZ or MenC-CRM Vaccination</measure>
    <time_frame>Within 30 minutes after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic AEs in Groups BC_35_12 and C_35_12 After Any rMenB+OMV NZ or MenC-CRM Vaccination</measure>
    <time_frame>Day 1 to day 7 after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_2h3h5_11, B_3h5_11 and B_68_11</measure>
    <time_frame>Until 12 months of age; Day 1 to day 7 (All AEs)</time_frame>
    <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV. Analysis was done on unsolicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_02_2_5 and B_02_6_10</measure>
    <time_frame>Day 1 to day 7 (All AEs). Throughout the study period (SAEs, medically attended or leading to premature withdrawal AEs)</time_frame>
    <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ. Analysis was done on unsolicited safety set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Group BC_35_12 and C_35_12</measure>
    <time_frame>Day 1 to Day 301 for BC_35_12 and C_35_12, Day 302 to Day 391 for C_35_12; Day 1 to day 7 (All AEs)</time_frame>
    <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on unsolicited safety set.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1409</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>B_2h3h5_11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_3h5_11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_68_11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_02_2_5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_02_6_10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BC_35_12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C_35_12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
    <arm_group_label>B_2h3h5_11</arm_group_label>
    <other_name>rMenB for Group I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>2 doses (3.5, 5 months of age) plus booster (11 months of age)</description>
    <arm_group_label>B_3h5_11</arm_group_label>
    <other_name>rMenB for Group II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>2 doses (6, 8 months of age) plus booster (11 months of age)</description>
    <arm_group_label>B_68_11</arm_group_label>
    <other_name>rMenB for Group III</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>2 doses 2 months apart</description>
    <arm_group_label>B_02_2_5</arm_group_label>
    <arm_group_label>B_02_6_10</arm_group_label>
    <other_name>rMenB for Group IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal C oligosaccharide conjugated vaccine</intervention_name>
    <description>Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine</description>
    <arm_group_label>BC_35_12</arm_group_label>
    <arm_group_label>C_35_12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.</intervention_name>
    <description>Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.</description>
    <arm_group_label>BC_35_12</arm_group_label>
    <arm_group_label>C_35_12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>Schedule 3, 5, 12 rMenB + OMV vaccine</description>
    <arm_group_label>BC_35_12</arm_group_label>
    <other_name>rMenB for Group V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB + OMV NZ vaccine</intervention_name>
    <description>Schedule 13,15 rMenB + OMV vaccine</description>
    <arm_group_label>C_35_12</arm_group_label>
    <other_name>rMenB for Group VI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy infants and children according to the following age groups:

               -  Healthy infants 2½ months of age (71 -79 days, inclusive), (only applicable to
                  group I)

               -  Healthy infants 3½ months of age (101 -109 days, inclusive), (only applicable to
                  group II)

               -  Healthy infants 6 months of age (only applicable to group III) (The age window is
                  defined as the first day the subject turns 6 months of age up to the day before
                  the subject turns 7 months of age).

               -  Healthy children 2 to 5 years of age (only applicable to group IVa) (The age
                  window is defined as the first day the subject turns 2 years of age up to the day
                  before the subject turns 6 years of age).

               -  Healthy children 6 to 10 years of age (only applicable to group IVb) (The age
                  window is defined as the first day the subject turns 6 years of age up to the day
                  before the subject turns 11 years of age).

               -  Healthy infants 3 months of age (83-104 days, inclusive), (only applicable to
                  Group V and VI).

          2. For whom parent(s)/legal guardian(s) have given written informed consent according to
             local regulations after the nature of the study has been explained;

          3. Available for all the visits scheduled in the study;

          4. Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Exclusion Criteria:

          1. Individuals whose parent(s)/legal guardian(s) are unwilling or unable to give written
             informed consent to participate in the study;

          2. Children's parents or legal guardian who are not able to comprehend and to follow all
             required study procedures for the whole period of the study.

          3. History of any meningococcal B vaccine administration;

          4. Previous ascertained or suspected disease caused by N. meningitidis;

          5. Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis;

          6. History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component

          7. Significant acute or chronic infection within the previous 7 days or temperature 38° C
             within the previous day of receiving the study vaccine;

          8. Antibiotics treatment within 6 days prior to enrollment;

          9. Individuals with history of allergy to vaccine components.

         10. Any serious chronic or progressive disease according to the judgment of the
             investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic
             disease, neurological disease or seizure, either associated with fever or as part of
             an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or
             AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe
             malnutrition);

         11. Known or suspected impairment/alteration of the immune system, immunosuppressive
             therapy, use of high dose systemic corticosteroids or chronic use of inhaled
             high-potency corticosteroids within 14 days prior to enrollment (use of low or
             moderate doses of inhaled steroids is not an exclusion);

         12. Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation within 90 days prior to enrollment.

         13. Receipt of, or intent to immunize with, any other vaccine(s) within 7 days prior to
             enrollment.

         14. Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or intent to participate in another clinical study
             at any time during the conduct of this study.

         15. Family members and household members of research staff

         16. Individuals with history or any illness that, in the opinion of the investigator,
             might interfere with the results of the study or pose additional risk to the subjects
             due to participation in the study.

         17. History of any meningococcal C vaccine administration (Only applicable to group V and
             VI).

         18. History of any Pneumococcal vaccine administration (Only applicable to group V and
             VI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>71 Days</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 55 - Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)</name>
      <address>
        <city>Rua dos Coelhos, 300 - Boa Vista</city>
        <state>Recife/PE</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 54- Associação Obras Sociais Irmã Dulce, Avenida Bonfim, nº 161</name>
      <address>
        <city>Largo de Roma</city>
        <state>Salvador/BA-CEP</state>
        <zip>40420-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53 - CRIE UNIFESP</name>
      <address>
        <city>Rua Borges Lagoa 770</city>
        <state>Sao Paulo</state>
        <zip>04038002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50 - Associacao Fundo de Incentivo a Psicofarmacologia</name>
      <address>
        <city>Rua Marselhesa 500 Vila Clementino</city>
        <state>Sao Paulo</state>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37 - Praxis Dr Julianna Kovacs</name>
      <address>
        <city>Honved utca 2</city>
        <state>Bordany</state>
        <zip>6795</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40 - General Pediatric Practice Hacsek</name>
      <address>
        <city>Poth Iren u 80</city>
        <state>Budapest</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42 - Praxis Dr Eszter Bari</name>
      <address>
        <city>Szentharomsag ter 10</city>
        <state>Csongrad</state>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34 - General Pediatric Practice Somorjai</name>
      <address>
        <city>Bajcsi ut 32</city>
        <state>Debrecen</state>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32 - Praxis Dr Eleonora Konya</name>
      <address>
        <city>Fo utca 12</city>
        <state>Malyi</state>
        <zip>3434</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31 - General Practice Dr Olga Fekete</name>
      <address>
        <city>Kando Kalman utca 1</city>
        <state>Miskolc</state>
        <zip>3534</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30 - General Practice Dr Simko</name>
      <address>
        <city>Selyemret u. 1.</city>
        <state>Miskolc</state>
        <zip>3527</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33 - General Pediatric Practice Ujhelyi</name>
      <address>
        <city>Szent Istvan u 10</city>
        <state>Nyiregyhaza</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35 - Praxis Dr Eva Kovacs</name>
      <address>
        <city>Csongradi sgt 63</city>
        <state>Szeged</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36 - General Practice Dr Edit Oszlacs</name>
      <address>
        <city>Debreceni utca 10-14</city>
        <state>Szeged</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80 - Hospital Nacional docente Madre Nino San Bartolome</name>
      <address>
        <city>Av Alfonso Ugarte</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 82 - Investigaciones Medicas en Salud INMENSA</name>
      <address>
        <city>Jr Jose de la Torre Ugarte Lince</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81 - Via Libre</name>
      <address>
        <city>Jr Paraguay Cercado de Lima</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Almeria</city>
        <zip>04007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Almeria</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Barcelona</city>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Peru</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <disposition_first_submitted>February 3, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 3, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 23, 2015</disposition_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease</keyword>
  <keyword>Vaccines</keyword>
  <keyword>intercalated administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in a total of a total of 26 sites; 4 sites in Brazil, 3 sites in Peru, 10 sites in Hungary, 9 sites in Spain.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B_2h3h5_11</title>
          <description>Subjects, approximately 2.5 months of age received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="P2">
          <title>B_3h5_11</title>
          <description>Subjects, approximately 3.5 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="P3">
          <title>B_68_11</title>
          <description>Subjects, approximately 6 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="P4">
          <title>B_02_2_5</title>
          <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="P5">
          <title>B_02_6_10</title>
          <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="P6">
          <title>BC_35_12</title>
          <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.</description>
        </group>
        <group group_id="P7">
          <title>C_35_12</title>
          <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="251"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="300"/>
                <participants group_id="P6" count="126"/>
                <participants group_id="P7" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="234"/>
                <participants group_id="P3" count="243"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="295"/>
                <participants group_id="P6" count="117"/>
                <participants group_id="P7" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Classify</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B_2h3h5_11</title>
          <description>Subjects, approximately 2.5 months of age received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="B2">
          <title>B_3h5_11</title>
          <description>Subjects, approximately 3.5 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="B3">
          <title>B_68_11</title>
          <description>Subjects, approximately 6 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="B4">
          <title>B_02_2_5</title>
          <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="B5">
          <title>B_02_6_10</title>
          <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="B6">
          <title>BC_35_12</title>
          <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.</description>
        </group>
        <group group_id="B7">
          <title>C_35_12</title>
          <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.</description>
        </group>
        <group group_id="B8">
          <title>TOTAL</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="253"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="251"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="300"/>
            <count group_id="B6" value="126"/>
            <count group_id="B7" value="125"/>
            <count group_id="B8" value="1409"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="0.1"/>
                    <measurement group_id="B2" value="3.0" spread="0.1"/>
                    <measurement group_id="B3" value="6.0" spread="0.0"/>
                    <measurement group_id="B4" value="47.5" spread="13.4"/>
                    <measurement group_id="B5" value="96.9" spread="16.8"/>
                    <measurement group_id="B6" value="3.0" spread="0.2"/>
                    <measurement group_id="B7" value="3.0" spread="0.1"/>
                    <measurement group_id="B8" value="26.6" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="149"/>
                    <measurement group_id="B6" value="74"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="151"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="66"/>
                    <measurement group_id="B8" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of rMenB+OMV Vaccination.</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254 and hSBA titers ≥ 5 against strain M10713 following 2-dose primary series of vaccination with rMenB+OMV NZ at 3.5 and 5 months of age or at 6 and 8 months of age. Analysis was done on Full analysis set (FAS)-Primary series.</description>
        <time_frame>1 month after second vaccination</time_frame>
        <population>FAS-Primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of rMenB+OMV Vaccination.</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254 and hSBA titers ≥ 5 against strain M10713 following 2-dose primary series of vaccination with rMenB+OMV NZ at 3.5 and 5 months of age or at 6 and 8 months of age. Analysis was done on Full analysis set (FAS)-Primary series.</description>
          <population>FAS-Primary series</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4; N=228, 234))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 4; N=230, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5; N=181, 192))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="35" upper_limit="52"/>
                    <measurement group_id="O2" value="73" lower_limit="65" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 4, hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 3-dose Primary Series of rMenB+OMV Vaccination</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713, following 3-dose primary series of vaccination with rMenB+OMV NZ at 2.5, 3.5 and 5 months of age. Analysis was done on FAS-primary series.</description>
        <time_frame>1 month after third vaccination</time_frame>
        <population>FAS-primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 4, hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 3-dose Primary Series of rMenB+OMV Vaccination</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713, following 3-dose primary series of vaccination with rMenB+OMV NZ at 2.5, 3.5 and 5 months of age. Analysis was done on FAS-primary series.</description>
          <population>FAS-primary series</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4; 1 month after 3rd vacc; N=237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4; 1 month after 3rd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 4; 1 month after 3rd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5; 1 month after 3rd vacc; N=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="48" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥ 8; 1 month after 3rd vacc; N=237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 8; 1 month after 3rd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 8; 1 month after 3rd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="85" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 8; 1 month after 3rd vacc; N=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="40" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule). Analysis was done on FAS-primary series.</description>
        <time_frame>1 month after second vaccination</time_frame>
        <population>FAS-primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_02</title>
            <description>Subjects, 2-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) and hSBA ≥ 8 Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule). Analysis was done on FAS-primary series.</description>
          <population>FAS-primary series</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4; 1 month after 2nd vacc; N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 4; 1 month after 2nd vacc; N=389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5; 1 month after 2nd vacc; N=370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="91" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥ 8; 1 month after 2nd vacc; N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 8; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 8; 1 month after 2nd vacc; N=389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 8; 1 month after 2nd vacc; N=370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="89" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving Four-fold Rise Over Baseline hSBA Titers Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects achieving 4-fold increase in hSBA titers as compared to baseline against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule).
Analysis was done on FAS- primary series.</description>
        <time_frame>1 month after second vaccination</time_frame>
        <population>FAS- primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_02</title>
            <description>Subjects, 2-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving Four-fold Rise Over Baseline hSBA Titers Following a 2-dose Catch-up Series of rMenB+OMV Vaccination</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects achieving 4-fold increase in hSBA titers as compared to baseline against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, M10713; following 2-dose catch-up series of vaccination with rMenB+OMV NZ in healthy children aged 2-10 years (0, 2 month schedule).
Analysis was done on FAS- primary series.</description>
          <population>FAS- primary series</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (1 month after 2nd vacc; N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (1 month after 2nd vacc; N=387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (1 month after 2nd vacc; N=352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="41" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) Following 2 or 3 Dose Primary Series of Vaccination With rMenB+OMV</title>
        <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains following 2 or 3 dose primary series of vaccination rMenB+OMV NZ (1 month after 3rd infant vaccination in B_2h3h5_11 and 1 month after 2nd infant vaccination in B_3h5_11, B_68_11 and B_02).
Analysis was done on FAS-primary series.</description>
        <time_frame>1 month after primary series vaccination</time_frame>
        <population>FAS-primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3.5, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O4">
            <title>B_02</title>
            <description>Subjects, 2-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) Following 2 or 3 Dose Primary Series of Vaccination With rMenB+OMV</title>
          <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains following 2 or 3 dose primary series of vaccination rMenB+OMV NZ (1 month after 3rd infant vaccination in B_2h3h5_11 and 1 month after 2nd infant vaccination in B_3h5_11, B_68_11 and B_02).
Analysis was done on FAS-primary series.</description>
          <population>FAS-primary series</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (1 month after primary vacc; N=237,228,234,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="92" upper_limit="130"/>
                    <measurement group_id="O2" value="132" lower_limit="110" upper_limit="158"/>
                    <measurement group_id="O3" value="240" lower_limit="201" upper_limit="287"/>
                    <measurement group_id="O4" value="121" lower_limit="109" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (1 month after primary vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="795" lower_limit="665" upper_limit="950"/>
                    <measurement group_id="O2" value="605" lower_limit="502" upper_limit="729"/>
                    <measurement group_id="O3" value="1157" lower_limit="964" upper_limit="1390"/>
                    <measurement group_id="O4" value="489" lower_limit="442" upper_limit="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 1m after primary vacc; N=238,230,233,389</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="28" upper_limit="42"/>
                    <measurement group_id="O2" value="39" lower_limit="31" upper_limit="48"/>
                    <measurement group_id="O3" value="65" lower_limit="52" upper_limit="80"/>
                    <measurement group_id="O4" value="42" lower_limit="38" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 1 m after primary vacc; N=197,181,192,370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="3.62" upper_limit="6.54"/>
                    <measurement group_id="O2" value="3.39" lower_limit="2.48" upper_limit="4.64"/>
                    <measurement group_id="O3" value="9.96" lower_limit="7.33" upper_limit="14"/>
                    <measurement group_id="O4" value="35" lower_limit="31" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) After First Infant Vaccination With rMenB+OMV.</title>
        <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (after 1 month for group B_2h3h5_11b, 1.5 months for group B_2h3h5_11b and 2 months for group B_68_11b). Analysis was done on FAS-post first dose.</description>
        <time_frame>1, 1.5 or 2 months after first infant vaccination</time_frame>
        <population>FAS-post first dose</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11b</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 3.5, 6, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11b</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 5, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (3.5, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11b</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age. Blood draw at 8, 9, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) After First Infant Vaccination With rMenB+OMV.</title>
          <description>Immunogenicity was assessed in terms of Geometric mean hSBA titers (GMTs) against N meningitidis serogroup B indicator strains after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (after 1 month for group B_2h3h5_11b, 1.5 months for group B_2h3h5_11b and 2 months for group B_68_11b). Analysis was done on FAS-post first dose.</description>
          <population>FAS-post first dose</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 1 month after 1st vacc; N=117,115,117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" lower_limit="3.29" upper_limit="5.35"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.41" upper_limit="7.37"/>
                    <measurement group_id="O3" value="9.83" lower_limit="7.59" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 1 month after 1st vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="27"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O3" value="37" lower_limit="27" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 1 month after 1st vacc; N=118,114,117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.32" upper_limit="3.54"/>
                    <measurement group_id="O2" value="2.48" lower_limit="1.98" upper_limit="3.11"/>
                    <measurement group_id="O3" value="2.84" lower_limit="2.28" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 1 month after 1st vacc; N=95,99,95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="1.86" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.21" upper_limit="2.36"/>
                    <measurement group_id="O3" value="1.62" lower_limit="1.15" upper_limit="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 After First Infant Vaccination With rMenB+OMV</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (at 3.5, 5, and 8 months of age respectively). Analysis was done on FAS-post first dose.</description>
        <time_frame>Post- first dose (1 month for B_2h3h5_11b, 1.5 month for B_3h5_11b and 2 months for B_68_11b after 1st vaccination)</time_frame>
        <population>FAS-post first dose</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11b</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 3.5, 6, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11b</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 5, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11b</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age. Blood draw at 8, 9, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 After First Infant Vaccination With rMenB+OMV</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254, hSBA titers ≥ 5 against strain M10713 and hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 after the first infant vaccination in groups B_2h3h5_11b, B_3h5_11b and B_68_11b (at 3.5, 5, and 8 months of age respectively). Analysis was done on FAS-post first dose.</description>
          <population>FAS-post first dose</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4; Post 1st vacc; N=117,115,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="52" upper_limit="70"/>
                    <measurement group_id="O2" value="72" lower_limit="63" upper_limit="80"/>
                    <measurement group_id="O3" value="82" lower_limit="74" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4; Post 1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O2" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O3" value="92" lower_limit="86" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 4; Post 1st vacc; N=118,114,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="34" upper_limit="53"/>
                    <measurement group_id="O2" value="39" lower_limit="30" upper_limit="48"/>
                    <measurement group_id="O3" value="41" lower_limit="32" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5; Post1st vacc; N=95,99,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="21" upper_limit="41"/>
                    <measurement group_id="O2" value="18" lower_limit="11" upper_limit="27"/>
                    <measurement group_id="O3" value="17" lower_limit="10" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥ 8; Post 1st vacc; N=117,115,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="17" upper_limit="34"/>
                    <measurement group_id="O2" value="38" lower_limit="29" upper_limit="48"/>
                    <measurement group_id="O3" value="58" lower_limit="49" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 8; Post1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="73" upper_limit="88"/>
                    <measurement group_id="O2" value="90" lower_limit="82" upper_limit="94"/>
                    <measurement group_id="O3" value="86" lower_limit="79" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 8; 1st vacc; N=118,114,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7" upper_limit="20"/>
                    <measurement group_id="O2" value="7" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O3" value="13" lower_limit="7" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 8; Post1st vacc; N=95,99,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13" upper_limit="31"/>
                    <measurement group_id="O2" value="15" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O3" value="13" lower_limit="7" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 Following a Booster Dose of rMenB+OMV Vaccination</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following a booster dose of rMenB+OMV NZ given at 11 months of age (4th dose for B_2h3h5_11 and 3rd dose for B_3h5_11 and B_68_11). Analysis was done on FAS-booster.</description>
        <time_frame>1 month post-booster dose</time_frame>
        <population>FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 and hSBA ≥ 8 Following a Booster Dose of rMenB+OMV Vaccination</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following a booster dose of rMenB+OMV NZ given at 11 months of age (4th dose for B_2h3h5_11 and 3rd dose for B_3h5_11 and B_68_11). Analysis was done on FAS-booster.</description>
          <population>FAS-booster</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4, after booster; N=233,227,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4, after booster)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 4, after booster; N=231,226,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5, after booster; N=203,181,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="77" upper_limit="88"/>
                    <measurement group_id="O2" value="87" lower_limit="81" upper_limit="91"/>
                    <measurement group_id="O3" value="83" lower_limit="77" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥ 8, after booster; N=233,227,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 8, after booster)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥ 8, after booster; N=231,226,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O3" value="97" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 8, after booster; N=203,181,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="72" upper_limit="84"/>
                    <measurement group_id="O2" value="83" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O3" value="74" lower_limit="67" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Persistence in Terms of Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</title>
        <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ vaccine. Analysis was done on FAS-persistence.</description>
        <time_frame>11 months of age (persistence)</time_frame>
        <population>FAS-persistence</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3.5, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence in Terms of Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</title>
          <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713 in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ vaccine. Analysis was done on FAS-persistence.</description>
          <population>FAS-persistence</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥ 4; 11 months of age; N=235,232,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="82" upper_limit="91"/>
                    <measurement group_id="O2" value="86" lower_limit="81" upper_limit="90"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 4; 11 months of age; N=234,230,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="89" upper_limit="96"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 hSBA≥ 4; 11 months of age; N=233,233,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="47" upper_limit="60"/>
                    <measurement group_id="O2" value="41" lower_limit="34" upper_limit="47"/>
                    <measurement group_id="O3" value="90" lower_limit="85" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 5; 11 months of age; N=199,177,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="26" upper_limit="40"/>
                    <measurement group_id="O2" value="23" lower_limit="17" upper_limit="30"/>
                    <measurement group_id="O3" value="42" lower_limit="35" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥ 8; 11 months of age; N=235,232,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="58" upper_limit="70"/>
                    <measurement group_id="O2" value="60" lower_limit="53" upper_limit="66"/>
                    <measurement group_id="O3" value="96" lower_limit="93" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥ 8; 11 months of age; N=234,230,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O2" value="87" lower_limit="82" upper_limit="91"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 hSBA≥ 8; 11 months of age; N=233,233,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="30" upper_limit="43"/>
                    <measurement group_id="O2" value="12" lower_limit="8" upper_limit="17"/>
                    <measurement group_id="O3" value="65" lower_limit="58" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥ 8; 11 months of age; N=199,177,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O3" value="36" lower_limit="29" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Persistence in Terms of Geometric Mean Titers Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</title>
        <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of GMTs against N meningitidis serogroup B indicator strains in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ. Analysis was done on FAS-persistence.</description>
        <time_frame>11 months of age (persistence)</time_frame>
        <population>FAS-persistence</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3.5, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence in Terms of Geometric Mean Titers Following 2 or 3-dose Primary Series of Vaccination With rMenB+OMV NZ</title>
          <description>Persistence of bactericidal antibodies at 11 months of age was assessed in terms of GMTs against N meningitidis serogroup B indicator strains in subjects who previously received a primary series of 2 or 3-doses of rMenB+OMV NZ. Analysis was done on FAS-persistence.</description>
          <population>FAS-persistence</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (Baseline; N=111,113,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.09" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.11" upper_limit="1.62"/>
                    <measurement group_id="O3" value="1.58" lower_limit="1.32" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (11 moa; N=235,232,237))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.64" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="9.39" upper_limit="14"/>
                    <measurement group_id="O3" value="67" lower_limit="55" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Baseline; N=113,112,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.02" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.16" lower_limit="1.02" upper_limit="1.32"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.85" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (11 moa; N=234,230,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="78" upper_limit="124"/>
                    <measurement group_id="O2" value="50" lower_limit="39" upper_limit="63"/>
                    <measurement group_id="O3" value="285" lower_limit="225" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Baseline; N=113,113,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.99" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.96" upper_limit="1.12"/>
                    <measurement group_id="O3" value="1" lower_limit="0.93" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (11 moa; N=233,233,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" lower_limit="3.66" upper_limit="5.71"/>
                    <measurement group_id="O2" value="2.68" lower_limit="2.13" upper_limit="3.38"/>
                    <measurement group_id="O3" value="12" lower_limit="9.79" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Baseline; N=84,64,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="1.75" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.52" lower_limit="1.07" upper_limit="2.17"/>
                    <measurement group_id="O3" value="1.29" lower_limit="0.95" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (11 moa; N=199,177,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" lower_limit="1.89" upper_limit="3.43"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.45" upper_limit="2.71"/>
                    <measurement group_id="O3" value="3.62" lower_limit="2.66" upper_limit="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following 2 or 3-dose Primary Series and Booster Dose of Vaccination With rMenB+OMV NZ</title>
        <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, following 2 or 3 dose primary series and booster dose of rMenB+OMV NZ. Analysis was done on FAS-persistence and FAS-booster.</description>
        <time_frame>1 month after primary vaccination, pre-booster vaccination (persistence) and 1 month after booster vaccination</time_frame>
        <population>FAS-persistence and FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following 2 or 3-dose Primary Series and Booster Dose of Vaccination With rMenB+OMV NZ</title>
          <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, following 2 or 3 dose primary series and booster dose of rMenB+OMV NZ. Analysis was done on FAS-persistence and FAS-booster.</description>
          <population>FAS-persistence and FAS-booster</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month after primary vaccination (N=212,215,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4688" lower_limit="3884" upper_limit="5660"/>
                    <measurement group_id="O2" value="3152" lower_limit="2594" upper_limit="3831"/>
                    <measurement group_id="O3" value="4682" lower_limit="3850" upper_limit="5694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster vaccination (N=213,220,215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474" lower_limit="395" upper_limit="569"/>
                    <measurement group_id="O2" value="291" lower_limit="241" upper_limit="351"/>
                    <measurement group_id="O3" value="1270" lower_limit="1052" upper_limit="1533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after booster dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5900" lower_limit="5047" upper_limit="6898"/>
                    <measurement group_id="O2" value="6062" lower_limit="5150" upper_limit="7135"/>
                    <measurement group_id="O3" value="5898" lower_limit="5016" upper_limit="6934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 After a Two Dose Catch-up rMenB+OMV NZ Immunization Series in Children 2-10 Years of Age</title>
        <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, after a two dose catch-up immunization series with rMenB+OMV NZ in children 2-10 years of age. Analysis was done on FAS-primary series.</description>
        <time_frame>1 month after second vaccination</time_frame>
        <population>FAS-primary series</population>
        <group_list>
          <group group_id="O1">
            <title>B_02</title>
            <description>Subjects, 2-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 After a Two Dose Catch-up rMenB+OMV NZ Immunization Series in Children 2-10 Years of Age</title>
          <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations (GMCs) against N meningitidis serogroup B vaccine antigen 287-953, after a two dose catch-up immunization series with rMenB+OMV NZ in children 2-10 years of age. Analysis was done on FAS-primary series.</description>
          <population>FAS-primary series</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2333" lower_limit="2124" upper_limit="2562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 8 Against Serogroup C Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</title>
        <description>Non-inferiority of MenC-CRM was determined following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months, as measured by the percentages of subjects achieving hSBA titers ≥ 8 against serogroup C. Analysis was done on PPS-primary series and PPS-booster.</description>
        <time_frame>Baseline, 1 month after second vaccination and 1 month after booster vaccination</time_frame>
        <population>PPS-primary series and PPS-booster.</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 8 Against Serogroup C Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</title>
          <description>Non-inferiority of MenC-CRM was determined following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months, as measured by the percentages of subjects achieving hSBA titers ≥ 8 against serogroup C. Analysis was done on PPS-primary series and PPS-booster.</description>
          <population>PPS-primary series and PPS-booster.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup C (1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (1 month after booster vacc; N=70,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of MenC-CRM was determined following co-administration of MenC-CRM and rMenB+OMV NZ vs MenC-CRM control group at 1 month after 2nd vaccination for serogroup C.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority.</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of MenC-CRM was determined following co-administration of MenC-CRM and rMenB+OMV NZ vs MenC-CRM control group at 1 month after booster vaccination for serogroup C.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority.</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</title>
        <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
        <time_frame>1 month after second vaccination, 1 month after booster vaccination</time_frame>
        <population>FAS-primary series and FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone</title>
          <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
          <population>FAS-primary series and FAS-booster</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month after 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568" lower_limit="461" upper_limit="701"/>
                    <measurement group_id="O2" value="905" lower_limit="718" upper_limit="1141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster vacc (N=92,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28" upper_limit="47"/>
                    <measurement group_id="O2" value="56" lower_limit="41" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after booster vacc (N=99,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201" lower_limit="991" upper_limit="1456"/>
                    <measurement group_id="O2" value="1724" lower_limit="1350" upper_limit="2201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone - Persistence</title>
        <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
        <time_frame>Pre-booster vaccination (persistence; 12 months of age)</time_frame>
        <population>FAS-persistence</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 ad 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM or MenC-CRM Alone - Persistence</title>
          <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ or MenC-CRM alone at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
          <population>FAS-persistence</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28" upper_limit="46"/>
                    <measurement group_id="O2" value="56" lower_limit="41" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and a booster at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
        <time_frame>1 month after second vaccination and 1 month after booster vaccination</time_frame>
        <population>FAS-primary series and FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 4 or hSBA Titers ≥ 5 (M10713) and hSBA ≥ 8 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects with hSBA titers ≥ 4 against N meningitidis serogroup B strains H44/76, 5/99, NZ98/254; hSBA titers ≥ 5 against strain M10713; hSBA titers ≥ 8 against strains H44/76, 5/99, NZ98/254, M10713; following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and a booster at 12 months. Analysis was done on FAS-primary series and FAS-booster.</description>
          <population>FAS-primary series and FAS-booster</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (hSBA≥4; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥4; 1 month after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥4; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥4; 1 month after booster vacc; N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥4; 1 month after 2nd vacc; N=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥4; 1 mo after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥5; 1 month after 2nd vacc; N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="58" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥5; 1 month after booster vacc; N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="57" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥8; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (hSBA≥8; 1 month after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥8; 1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA≥8; 1 month after booster vacc; N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥8; 1 month after 2nd vacc; N=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA≥8; 1 mo after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥8; 1 month after 2nd vacc; N=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="50" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA≥8; 1 month after booster vacc; N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs Against N. Meningitidis Serogroup B Strains Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
        <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence and FAS-booster.</description>
        <time_frame>1 month after second vaccination, pre-booster vaccination and 1 month after booster vaccination</time_frame>
        <population>FAS-persistence and FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs Against N. Meningitidis Serogroup B Strains Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
          <description>Immunogenicity was assessed in terms of GMTs against N meningitidis serogroup C strain following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence and FAS-booster.</description>
          <population>FAS-persistence and FAS-booster</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" lower_limit="179" upper_limit="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Pre-booster vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="13" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (1 month after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="198" upper_limit="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555" lower_limit="409" upper_limit="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Pre-booster vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="42" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (1 month after booster vacc; N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1623" lower_limit="1210" upper_limit="2176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (1 month after 2nd vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="21" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Pre-booster vacc; N=115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" lower_limit="2.21" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (1 month after booster vacc; N=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="54" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (1 month after 2nd vacc; N=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" lower_limit="7.06" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Pre-booster vacc; N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.72" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (1 month after booster vacc; N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.72" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
        <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary and FAS-booster.</description>
        <time_frame>1 month after second vaccination, pre-booster vaccination and 1 month after booster vaccination</time_frame>
        <population>FAS-primary and FAS-booster</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM</title>
          <description>Immunogenicity was assessed in terms of Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-primary and FAS-booster.</description>
          <population>FAS-primary and FAS-booster</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month after 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2125" lower_limit="1595" upper_limit="2830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster vacc (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="164" upper_limit="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after booster vacc (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4281" lower_limit="3411" upper_limit="5372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM - Persistence</title>
        <description>Immunogenicity was assessed in terms of GMTs against Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
        <time_frame>Pre-booster vaccination (persistence; 12 months of age)</time_frame>
        <population>FAS-persistence</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Concentrations Against Vaccine Antigen 287-953 Following Concomitant Administration of rMenB+OMV NZ With MenC-CRM - Persistence</title>
          <description>Immunogenicity was assessed in terms of GMTs against Geometric mean ELISA concentrations against N meningitidis serogroup B vaccine antigen 287-953, following co-administration of MenC-CRM and rMenB+OMV NZ at 3 and 5 months and booster dose at 12 months. Analysis was done on FAS-persistence.</description>
          <population>FAS-persistence</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="166" upper_limit="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination With rMenB+OMV NZ</title>
        <description>Safety was assessed in terms of number of subjects who reported immediate reactions within 30 minutes following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
        <time_frame>Within 30 minutes after any vaccination</time_frame>
        <population>Solicited safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11b</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 3.5, 6, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11b</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 5, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11b</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age. Blood draw at 8, 9, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination With rMenB+OMV NZ</title>
          <description>Safety was assessed in terms of number of subjects who reported immediate reactions within 30 minutes following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain (N=252,248,250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp. (N=252,248,250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp. (N=252,248,250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following a 3 or 4-dose Regimen of rMenB+OMV NZ</title>
        <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or as a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
        <time_frame>Day 1 to day 7 after any vaccination</time_frame>
        <population>Solicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following a 3 or 4-dose Regimen of rMenB+OMV NZ</title>
          <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination following a 4-dose regimen (2.5, 3.5, 5 and 11 months) or as a 3-dose regimen (3.5, 5 and 11 months or 6, 8 and 11 months) of rMenB+OMV NZ. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp. (N=245,241,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp. (N=245,242,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination - Groups B_02_2_5 and B_02_6_10</title>
        <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2 - 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
        <time_frame>Within 30 minutes after any vaccination</time_frame>
        <population>Solicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>B_02_2_5</title>
            <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
          <group group_id="O2">
            <title>B_02_6_10</title>
            <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any Vaccination - Groups B_02_2_5 and B_02_6_10</title>
          <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2 - 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=0,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits (N=104,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=104,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=104,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=104,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=0,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=0,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea (N=104,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=0,300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic AEs in Groups B_02_2_5 and B_02_6_10</title>
        <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2- 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
        <time_frame>Day 1 to day 7 after any vaccination</time_frame>
        <population>Solicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>B_02_2_5</title>
            <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
          <group group_id="O2">
            <title>B_02_6_10</title>
            <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic AEs in Groups B_02_2_5 and B_02_6_10</title>
          <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination in subjects aged 2- 10 years who received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (N=100,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=0,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits (N=100,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=100,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=100,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=0,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=100,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=0,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=100,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="NA">Solicited AE not applicable for this age-group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=0,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Solicited AE not applicable for this age-group.</measurement>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp. (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp. (N=100,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any rMenB+OMV NZ or MenC-CRM Vaccination</title>
        <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
        <time_frame>Within 30 minutes after any vaccination</time_frame>
        <population>Solicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Immediate Reactions Within 30 Minutes After Any rMenB+OMV NZ or MenC-CRM Vaccination</title>
          <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness (rMenB+OMV NZ) (N=126,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (rMenB+OMV NZ) (N=126,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (rMenB+OMV NZ) (N=126,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (rMenB+OMV NZ) (N=126,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (MenC-CRM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (MenC-CRM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (MenC-CRM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (MenC-CRM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and Systemic AEs in Groups BC_35_12 and C_35_12 After Any rMenB+OMV NZ or MenC-CRM Vaccination</title>
        <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
        <time_frame>Day 1 to day 7 after any vaccination</time_frame>
        <population>Solicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic AEs in Groups BC_35_12 and C_35_12 After Any rMenB+OMV NZ or MenC-CRM Vaccination</title>
          <description>Safety was assessed in terms of number of subjects with solicited local and systemic AEs after any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on solicited safety set.</description>
          <population>Solicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local rMenB + OMZ NV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local MenC-CRM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (rMenB+OMV NZ) (N=123,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (rMenB+OMV NZ) (N=123,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (rMenB+OMV NZ) (N=123,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (rMenB+OMV NZ) (N=123,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="NA">Subjects in this group did not receive rMenB+OMV NZ vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (MenC-CRM) (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (MenC-CRM) (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (MenC-CRM) (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (MenC-CRM) (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used for pain (N=123,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to prevent high temp.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medic. used to treat high temp.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_2h3h5_11, B_3h5_11 and B_68_11</title>
        <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV. Analysis was done on unsolicited safety set.</description>
        <time_frame>Until 12 months of age; Day 1 to day 7 (All AEs)</time_frame>
        <population>Unsolicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>B_2h3h5_11b</title>
            <description>Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 3.5, 6, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O2">
            <title>B_3h5_11b</title>
            <description>Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age. Blood draw at 5, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (3-1/2, 5 months of age) plus booster (11 months of age)</description>
          </group>
          <group group_id="O3">
            <title>B_68_11b</title>
            <description>Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age. Blood draw at 8, 9, 11 and 12 months of age.
rMenB + OMV NZ vaccine: 2 doses (6, 8 months of age) plus booster (11 months of age)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_2h3h5_11, B_3h5_11 and B_68_11</title>
          <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV. Analysis was done on unsolicited safety set.</description>
          <population>Unsolicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs (days 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possible related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_02_2_5 and B_02_6_10</title>
        <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ. Analysis was done on unsolicited safety set.</description>
        <time_frame>Day 1 to day 7 (All AEs). Throughout the study period (SAEs, medically attended or leading to premature withdrawal AEs)</time_frame>
        <population>Unsolicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>B_02_2_5</title>
            <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
          <group group_id="O2">
            <title>B_02_6_10</title>
            <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
rMenB + OMV NZ vaccine: 2 doses 2 months apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Groups B_02_2_5 and B_02_6_10</title>
          <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ. Analysis was done on unsolicited safety set.</description>
          <population>Unsolicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs (days 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possible related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Group BC_35_12 and C_35_12</title>
        <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on unsolicited safety set.</description>
        <time_frame>Day 1 to Day 301 for BC_35_12 and C_35_12, Day 302 to Day 391 for C_35_12; Day 1 to day 7 (All AEs)</time_frame>
        <population>Unsolicited safety set</population>
        <group_list>
          <group group_id="O1">
            <title>BC_35_12</title>
            <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 3, 5, 12 rMenB + OMV vaccine</description>
          </group>
          <group group_id="O2">
            <title>C_35_12</title>
            <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
Meningococcal C oligosaccharide conjugated vaccine: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
rMenB + OMV NZ vaccine: Schedule 13,15 rMenB + OMV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs Following Any Vaccination With rMenB+OMV NZ in Group BC_35_12 and C_35_12</title>
          <description>Safety was assessed in terms of number of subjects reporting any unsolicited AEs (day 1-7 after any vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal from the study (collected throughout the study period) following any vaccination with rMenB+OMV NZ or MenC-CRM. Analysis was done on unsolicited safety set.</description>
          <population>Unsolicited safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs (days 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Till 12 months of age for groups B_2h3h5_11, B_3h5_11 and B_68_11; Day 1 to Day 91 for groups B02_2_5 and B02_6_10; Day 1 to Day 301 for group BC_35_12; Day 1 to Day 391 for group C_35_12.</time_frame>
      <desc>All solicited AEs were collected by systematic assessment and unsolicited AEs were collected by non-systematic assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>B_2h3h5_11</title>
          <description>Subjects, approximately 2.5 months of age received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="E2">
          <title>B_3h5_11</title>
          <description>Subjects, approximately 3.5 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="E3">
          <title>B_68_11</title>
          <description>Subjects, approximately 6 months of age received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.</description>
        </group>
        <group group_id="E4">
          <title>B_02_2_5</title>
          <description>Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="E5">
          <title>B_02_6_10</title>
          <description>Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.</description>
        </group>
        <group group_id="E6">
          <title>BC_35_12</title>
          <description>Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.</description>
        </group>
        <group group_id="E7">
          <title>C_35_12</title>
          <description>Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.</description>
        </group>
        <group group_id="E8">
          <title>TOTAL</title>
          <description>All subjects in the safety population.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="58" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CONGENITAL CENTRAL NERVOUS SYSTEM ANOMALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ROTAVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>COW'S MILK INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>JUVENILE IDIOPATHIC ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN INTRACRANIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>GENERALISED TONIC-CLONIC SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ADENOIDAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>CHOKING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>TONSILLAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="288" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="124" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="115" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1358" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="49" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="353" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="248" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="47" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>CRYING</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="105" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="93" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="739" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="123" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="180" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="62" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="828" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="124" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="650" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="287" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="114" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="102" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1147" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="146" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="545" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="117" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="117" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="99" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="77" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="827" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="61" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="68" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="122" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="65" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="46" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="95" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="151" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="61" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="57" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="66" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="59" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="60" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="287" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="85" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="85" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="127" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="127" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="97" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="93" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="84" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="698" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="64" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="540" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="79" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="714" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>CATARRH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="51" subjects_at_risk="1404"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="143" subjects_at_risk="1404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

